Next Article in Journal
Occurrence of Fusarium spp. and Fumonisins in Stored Wheat Grains Marketed in Iran
Next Article in Special Issue
Spider-Venom Peptides as Therapeutics
Previous Article in Journal
Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease
Previous Article in Special Issue
Novel Cytotoxic Vectors Based on Adeno-Associated Virus
Toxins 2010, 2(12), 2795-2815; doi:10.3390/toxins2122795
Review

Targeted Secretion Inhibitors—Innovative Protein Therapeutics

*  and
Received: 15 October 2010; in revised form: 16 November 2010 / Accepted: 2 December 2010 / Published: 3 December 2010
(This article belongs to the Special Issue Toxins as Therapeutics)
View Full-Text   |   Download PDF [260 KB, uploaded 3 December 2010]   |   Browse Figure
Abstract: Botulinum neurotoxins are highly effective therapeutic products. Their therapeutic success results from highly specific and potent inhibition of neurotransmitter release with a duration of action measured in months. These same properties, however, make the botulinum neurotoxins the most potent acute lethal toxins known. Their toxicity and restricted target cell activity severely limits their clinical utility. Understanding the structure-function relationship of the neurotoxins has enabled the development of recombinant proteins selectively incorporating specific aspects of their pharmacology. The resulting proteins are not neurotoxins, but a new class of biopharmaceuticals, Targeted Secretion Inhibitors (TSI), suitable for the treatment of a wide range of diseases where secretion plays a major role. TSI proteins inhibit secretion for a prolonged period following a single application, making them particularly suited to the treatment of chronic diseases. A TSI for the treatment of chronic pain is in clinical development.
Keywords: botulinum neurotoxins; biologics; protein therapeutics; recombinant proteins; genetic engineering; SNARE proteins botulinum neurotoxins; biologics; protein therapeutics; recombinant proteins; genetic engineering; SNARE proteins
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Keith, F.; John, C. Targeted Secretion Inhibitors—Innovative Protein Therapeutics. Toxins 2010, 2, 2795-2815.

AMA Style

Keith F, John C. Targeted Secretion Inhibitors—Innovative Protein Therapeutics. Toxins. 2010; 2(12):2795-2815.

Chicago/Turabian Style

Keith, Foster; John, Chaddock. 2010. "Targeted Secretion Inhibitors—Innovative Protein Therapeutics." Toxins 2, no. 12: 2795-2815.


Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert